Tick-borne encephalitis, prevention:
Primary immunization: Note: Complete the series ≥1 week prior to potential exposure to tick-borne encephalitis virus (TBEV).
Children and Adolescents <16 years: IM: 0.25 mL per dose administered as a 3-dose series with second dose given 1 to 3 months after the first dose, and the third dose given 5 to 12 months after the second dose.
Adolescents ≥16 years: IM: 0.5 mL per dose administered as a 3-dose series with the second dose given 14 days to 3 months after the first dose, and the third dose given 5 to 12 months after the second dose.
Booster immunization (for persons with continuous exposure or possible re-exposure to TBEV):
Children ≥4 years and Adolescents <16 years: IM: 0.25 mL as a single dose administered ≥3 years following completion of the primary series.
Adolescents ≥16 years: IM: 0.5 mL as a single dose administered ≥3 years following completion of the primary series.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Tick-borne encephalitis vaccine: Drug information")
Tick-borne encephalitis, prevention:
Primary immunization: IM: 0.5 mL per dose administered as a 3-dose series with the second dose given 14 days to 3 months after the first dose, and the third dose given 5 to 12 months after the second dose. Note: Complete the series ≥1 week prior to potential exposure to tick-borne encephalitis virus.
Booster immunization (for persons with continuous exposure or possible re-exposure to tick-borne encephalitis virus): IM: 0.5 mL as a single dose administered ≥3 years following completion of the primary series.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Suspension Prefilled Syringe, Intramuscular:
Ticovac: 2.4 mcg/0.5 mL (0.5 mL) [contains albumin human, chicken protein, formaldehyde solution, neomycin, protamine sulfate]
No
In the United States, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law.
Parenteral: IM: Allow vaccine to come to room temperature prior to administration. Shake well. Do not use if a homogenous off-white, opalescent suspension does not form. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (ACIP [Kroger 2021]).
Administer IM; preferred muscle for injection is based on age:
Children <3 years: IM injection in anterolateral thigh preferred; deltoid muscle can be used if muscle mass is adequate (ACIP [Kroger 2021]).
Children ≥3 years and Adolescents: IM injection in the deltoid muscle. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).
US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.
For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (≤23-gauge) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be cons
